Patients with Paroxysmal Nocturnal Hemoglobinuria research hub

A Long-term Extension (LTE) Study to Characterize the Safety and Efficacy of Danicopan as an Add-on Therapy to a Complement Component 5 Inhibitor (C5i) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Previously Treated with Danicopan in an Alexion-sponsored Clinical Study.

This study looks at a medicine called danicopan for adults with paroxysmal nocturnal hemoglobinuria (PNH). It is an extension study for people who already took danicopan in an earlier trial. Researchers want to see if continuing this add-on treatment alongside standard care remains safe and helpful over a longer period.